Drug intelligence / Profile preview

DUVAC

Development stage
Unknown
Lead developer
Orgenesis
Modality
Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Small Molecules
Administration
Injection
01

Overview

DUVAC is a therapeutic cellular vaccine platform developed by Orgenesis in collaboration with Columbia University for the treatment of pancreatic cancer and other solid tumors, including hepatic and cholangiocarcinoma. The platform utilizes a patented dual-vaccine design that combines whole cancer cells as a comprehensive source of antigens with the patient's own autologous dendritic cells and macrophages. These antigen-presenting cells are used to activate a T-cell-mediated immune response against the tumor. The preparation protocol involves a specific combination of chemotherapy agents—dexamethasone, urea, vincristine, doxorubicin, and carmustine—which are likely used to process the tumor cells or modulate the immune environment to enhance antigenicity. The therapy is currently in Phase 1/2 clinical development.

Other names
Cellular vaccineTherapeutic cellular vaccine platform
02

Targets

DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on DUVAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DUVAC.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call